September 29, 2016 / 10:37 PM / a year ago

BUZZ-Aurinia Pharmaceuticals Inc: Rises on positive study results

** Canadian drug developer's U.S.-listed shares up 14 pct at $3.01 after market

** Company says investigational drug Voclosporin achieved primary and all pre-specified secondary endpoints in its phase IIb AURA-LV study for lupus nephritis

** Lupus nephritis is a serious condition that involves inflammation of the kidney

** Up to Thursday's close, stock had risen about 7 pct this year

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below